Better Outcomes Through Improved Drug Delivery
EnduRx therapeutic candidates are polymeric nanoparticles designed to achieve tumor-specific delivery of active pharmaceutical ingredients (API’s) that internalize into cells throughout the tumor parenchyma while avoiding healthy tissue.
Published foundational studies by an accomplished institutional team showed significant tumor volume reduction and sometimes complete tumor elimination. EnduRx is building on these studies to develop nanoparticles with improved efficacy, safety and robustness.
Tumor-specific delivery of highly-toxic chemotherapy agents and other APIs would offer reduced systemic toxicity and thereby improve both drug efficacy and patient experience. Improved patient experience can increase compliance well as quality-of-life during treatment, potentially further improving outcomes.
Triple-negative breast cancer and other solid tumors
Ovarian cancer and
Glioblastoma and other brain tumors
Reduction of atherosclerotic plaque
Collaborations to improve delivery of existing approved therapeutics
The EnduRx peptide-directed polymeric nanoparticle platform technology offers the potential to improve tumor-specific delivery of a range other approved therapeutics and developmental candidates. EnduRx seeks collaborations with other companies interested in application of our drug delivery platform to their molecule.
As a virtual pre-clinical company, EnduRx utilizes resources across the US in locations including Boston, Memphis, Houston, Tucson, Phoenix and Scottsdale, San Diego and elsewhere.
EnduRx Pharmaceuticals Inc.
8340 N Thornydale Rd Suite 110-328
Tucson, AZ 85741
phone: (855) 368-2878
(be prepared to leave a voicemail)
Please do not mail unsolicited materials to our Corporate Office address.
Contact should be initiated by email to
David Loynd, President & CEO:
dloynd at endurxpharm dot com
We welcome communication with the potential to add value but persistent unwanted solicitation and spam will be blocked.